Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Meta Description: Ewing’s sarcoma, or Ewing’s family of tumors, is the second most common bone cancer in children. Great strides have been made in the treatment of patients with Ewing’s sarcoma, particularly for children with localized disease at presentation, for whom intensified, 5 drug alternating chemotherapy with aggressive local control has yielded a 5 year event free survival of 76%.
Despite novel chemotherapeutic strategies employing new agents such as topotecan on top of the most successful treatment backbone (NCT01231906), it is likely that there will be a plateau in the disease benefit associated with intensified chemotherapy for children with Ewing’s sarcoma. For children with metastatic disease at presentation, the situation is only worse. This situation mirrors that in many pediatric cancers, hence the crucial need to study new agents in pediatric cancer. For adolescents and young adults with this disease, the rate of progress has been particularly slow.
For more details:
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi